張 家崙

Medicine & Life Sciences

1. Chemoradiotherapy 100%
2. Propensity Score 90%
3. Radiotherapy 71%
4. Survival 59%
5. Cohort Studies 57%
6. Taiwan 51%
7. Intensity-Modulated Radiotherapy 48%
8. Neoplasms 47%
9. Head and Neck Neoplasms 41%
10. Esophageal Squamous Cell Carcinoma 40%
11. Adenocarcinoma of Lung 37%
12. Squamous Cell Carcinoma of Head and Neck 34%
13. Population 34%
14. ErbB Receptors 34%
15. Confidence Intervals 33%
16. Adenocarcinoma 33%
17. Therapeutics 31%
18. Thorax 30%
19. Hepatocellular Carcinoma 29%
20. Adjuvant Radiotherapy 29%
21. Drug Therapy 29%
22. Breast Neoplasms 27%
23. Regression Analysis 25%
24. fucoidan 25%
25. Protein-Tyrosine Kinases 24%
26. Neoplasm Metastasis 23%
27. Chronic Pain 23%
28. Pelvic Organ Prolapse 21%
29. Squamous Cell Carcinoma 21%
30. Fish Oils 20%
31. Adjuvant Chemotherapy 20%
32. Cholangiocarcinoma 19%
33. tien-hsien liquid 19%
34. Cisplatin 19%
35. Databases 19%
36. Selenium 18%
37. Adjuvant Chemoradiotherapy 18%
38. Registries 18%
39. Radiosurgery 18%
40. Recurrence 18%
41. Lung 18%
42. Propofol 18%
43. Robotics 17%
44. Conduction Anesthesia 16%
45. Non-Small Cell Lung Carcinoma 16%
46. MicroRNAs 16%
47. Hydroxymethylglutaryl-CoA Reductase Inhibitors 16%
48. Lung Neoplasms 15%
49. Opioid Analgesics 15%
50. Antrodia 14%